<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638248</url>
  </required_header>
  <id_info>
    <org_study_id>PN01-CLD-000002/01</org_study_id>
    <nct_id>NCT00638248</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)</brief_title>
  <acronym>DEDAS</acronym>
  <official_title>International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase I/II Trial of Desmoteplase in the Indication of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PAION Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PAION Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to explore trends in safety and efficacy, and to find the
      optimal dose for the subsequent phase III trial. The decision to initiate the phase III trial
      will depend on both safety (incidence of symptomatic intracranial hemorrhage) and efficacy
      (reperfusion measured by MRI and correlating with clinical outcome) profiles. The safety
      (incidence of symptomatic intracranial haemorrhage) and efficacy (reperfusion measured by MRI
      and correlating with clinical outcome) profiles gained from this study were the basis of
      planning the phase III.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute stroke is the third leading cause of mortality in developed countries and the major
      medical cause of disability in adults. The outcome can be improved by early treatment with
      thrombolysis. Alteplase (r-tPA) is the only approved thrombolytic drug in the indication of
      acute ischemic stroke. However, the use of alteplase is currently restricted by the need to
      administer it within 3 hours of symptom onset. As the risk of transforming a cerebral infarct
      into haemorrhage probably rises as the time elapsed increases, a thrombolytic drug that
      carries a lower risk of haemorrhage than alteplase may offer a wider time-to-treatment window
      and improve the safety profile.

      Desmoteplase (DSPA) with its high fibrin specificity, lack of neurotoxicity, potential
      neuroprotective effect, non-activation by ß-amyloid, and long terminal half-life may account
      for an improved safety and efficacy profile within the first 9 hours after onset of symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS), Barthel-Index, mRS</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reperfusion after 4-8 h</measure>
    <time_frame>8 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Infarct lesion volume after 30 days</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety &amp; pharmacokinetic outcomes</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desmoteplase 90µg/kg BW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desmoteplase 125 µg/kg BW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmoteplase</intervention_name>
    <description>Desmoteplase 90µg/kg BW i.v. bolus</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmoteplase</intervention_name>
    <description>Desmoteplase 125 µg/kg BW i.v. bolus</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo i.v. bolus</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scoring 4 to 20 on the National Institute of Health Stroke Scale (NIHSS)

          -  showing a perfusion-diffusion mismatch on MRI of 20 %

          -  enrolment within a 3 h to 9 h time window after symptom onset.

          -  18-85 years of age

        Exclusion Criteria:

          -  Participation in any interventional trial in the previous 30 days.

          -  Women in the childbearing age.

          -  Any history of intracranial hemorrhage, subarachnoid hemorrhage, neoplasm,
             arteriovenous malformation or aneurysm.

          -  Conditions that, according to the judgment of the investigator, might impose an
             additional risk to any individual stroke patient when receiving study medication (this
             applied to patients on platelet-function inhibitors as well).

          -  MRI exclusion criteria: Evidence of ICH, Evidence of SAH, Signs of extensive early
             infarction on DWI assessed by evidence of involvement of &gt;1/3 of the middle cerebral
             artery (MCA) territory. No perfusion deficit, Internal carotid artery (ICA) occlusion
             ipsilateral to stroke lesion without additional ipsilateral MCA, anterior cerebral
             artery (ACA) or posterior cerebral artery (PCA) occlusion. Any intracranial pathology
             that would interfere with the MRI assessment of acute ischemic stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antony J. Furlan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology; the Cleveland Clinic Foundation</affiliation>
  </overall_official>
  <link>
    <url>http://stroke.ahajournals.org/cgi/reprint/37/5/1227</url>
    <description>Study Publication</description>
  </link>
  <link>
    <url>http://www.paion.de</url>
    <description>PAION Deutschland GmbH</description>
  </link>
  <results_reference>
    <citation>Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006 May;37(5):1227-31. Epub 2006 Mar 30.</citation>
    <PMID>16574922</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>March 12, 2008</last_update_submitted>
  <last_update_submitted_qc>March 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Karin Wilhelm-Ogunbiyi, MD / Medical Director &amp; Head of Clinical Development</name_title>
    <organization>PAION Deutschland GmbH</organization>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary plasminogen activator alpha 1, Desmodus rotundus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

